2-(4-methyl-benzyl)phenol | 56502-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methyl-benzyl)phenol
• 英文别名: 2-Hydroxy-4'-methyl-diphenylmethan；2-(4-Methylbenzyl)phenol；2-[(4-methylphenyl)methyl]phenol
• CAS: 56502-38-6
• 化学式: C₁₄H₁₄O
• 分子量: 198.265
• InChiKey: TVGZELAGISCEBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(4-methyl-benzyl)phenol 在 氢氧化钾 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 32.0h， 生成 N,N-dimethyl-4-[2-[(4-methylphenyl)methyl]phenoxy]butan-1-amine
  参考文献：
  名称：

  Synthesis and antidepressant activity of substituted (.omega.-aminoalkoxy)benzene derivatives

  摘要：

  A series of substituted (omega-aminoalkoxy)benzene derivatives has been synthesized and screened for potential antidepressant activities. The effect of structural variation of these molecules has been systematically examined. Antidepressant activity was clearly displayed by 2-benzyl-1-[4-(methylamino)butoxy]benzene (7), 2-(2-hydroxybenzyl)-1-[4-(methylamino)butoxy]benzene (19), 1-[4-(methylamino)butoxy]-2-phenoxybenzene (29), and 1-[4-(methylamino)butoxy]-2-(phenylthio)benzene (31) in further pharmacological studies. These compounds did not possess the anticholinergic, antihistaminic, and muscle-relaxant side effects common to tricyclic antidepressants.

  DOI：

  10.1021/jm00134a004
• 作为产物：
  描述：

  1-甲基-2-(4-甲基苯氧基)苯 在 三乙基硅烷 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以34%的产率得到2-(4-methyl-benzyl)phenol
  参考文献：
  名称：

  [Et3SiH + KOtBu]的苄基CH功能导致邻甲苯基芳醚，胺和硫化物的自由基重排

  摘要：

  Et 3 SiH + KO t Bu与具有邻烷基的二芳基醚，硫化物和胺的反应会导致重排产物。该重排是由苄基的形成引起的，该苄基的形成可能是通过三乙基甲硅烷基基团夺取氢原子而形成的。重排涉及将苄基环化到伙伴芳烃上，这从计算上是速率确定步骤。在二芳基醚的情况下，Truce-Smiles重排是由自由基环化形成的5元环，但对于二芳基胺，则观察到环化形成了二氢ac啶。

  DOI：

  10.1002/adsc.202000356

文献信息

• Ionic Liquids as Reagent and Reaction Medium: Preparation of Alkyl Aryl Ethers
  作者：Farajollah Mohanazadeh、Majid Aghvami

  DOI：10.1007/s00706-006-0562-5

  日期：2007.1

  Room temperature ionic liquid, [ bmIm ]OH, is used as a green recyclable reaction medium and reagent for the alkylation of phenols in excellent yields. The recovered ionic liquid was reused five to six times with consistent activity.

  室温离子液体[ bmIm ] OH被用作绿色可循环使用的反应介质和苯酚烷基化的试剂，收率很高。回收的离子液体以一致的活性重复使用五到六次。
• Benzylic C−H Functionalisation by [Et ₃ SiH+KO ^<i>t</i> Bu] leads to Radical Rearrangements in <i>o‐</i> tolyl Aryl Ethers, Amines and Sulfides
  作者：Jude N. Arokianathar、Krystian Kolodziejczak、Frances E. Bugden、Kenneth F. Clark、Tell Tuttle、John A. Murphy

  DOI：10.1002/adsc.202000356

  日期：2020.5.26

  rearrangement products. The rearrangements arise from formation of benzyl radicals, likely formed through hydrogen atom abstraction by triethylsilyl radicals. The rearrangements involve cyclisation of the benzyl radical onto the partner arene, which, from computation, is the rate determining step. In the case of diaryl ethers, Truce‐Smiles rearrangements arise from radical cyclisations to form 5‐membered

  Et 3 SiH + KO t Bu与具有邻烷基的二芳基醚，硫化物和胺的反应会导致重排产物。该重排是由苄基的形成引起的，该苄基的形成可能是通过三乙基甲硅烷基基团夺取氢原子而形成的。重排涉及将苄基环化到伙伴芳烃上，这从计算上是速率确定步骤。在二芳基醚的情况下，Truce-Smiles重排是由自由基环化形成的5元环，但对于二芳基胺，则观察到环化形成了二氢ac啶。
• Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
  申请人：——

  公开号：US20040018998A1

  公开（公告）日：2004-01-29

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein P represents a group forming a prodrug; and R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group, which have an improved oral absorption and can exert an excellent inhibitory activity in human SGLT2 in vivo and which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same.

  本发明涉及由通式表示的葡萄糖吡喃基氧基苯基苄基苯基衍生物：其中P代表形成前药的基团；R代表下位烷基基团、下位烷氧基基团、下位烷基硫基团、下位烷氧基取代的（下位烷基）基团、下位烷氧基取代的（下位烷氧基）基团或下位烷氧基取代的（下位烷基硫）基团，这些衍生物具有改善的口服吸收能力，在人体SGLT2中可以发挥出色的抑制活性，对于预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症等，以及包含这些衍生物的药物组合物，具有应用价值。
• O-aryl glucoside SGLT2 inhibitors and method
  申请人：——

  公开号：US20020111315A1

  公开（公告）日：2002-08-15

  1 wherein when Y is 2 or heteroaryl; A is —O(CH 2 ) m , S, —NH(CH 2 ) m , or (CH 2 ) n where n is 0-3 and m is 0-2; and R 1 to R 6 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents, and/or one, two or more hypolipidemic agents.

  提供一种方法，使用上述化合物的SGLT2抑制剂量单独或与一种、两种或更多其他抗糖尿病药物和/或一种、两种或更多降脂药物组合治疗糖尿病和相关疾病。其中，Y是2或杂环芳基；A是-O(CH2)m、S、-NH(CH2)m或(CH2)n，其中n为0-3，m为0-2；R1至R6如此定义。
• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：Fujikura Hideki

  公开号：US20050080022A1

  公开（公告）日：2005-04-14

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃基氧基苄基苯衍生物：其中R1表示氢原子或羟基（较低烷基）基团；R2表示较低烷基基团、较低烷氧基团、较低烷基硫基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐。该化合物在人类SGLT2中具有优异的抑制活性，可用作预防或治疗糖尿病、肥胖等的药物，以及其中间体。